Figure 6. DNA Demethylating Agent Treatment Prior to PD-L1 Blockade Enhances WT CD8 T-Cell Rejuvenation.

(A) Experimental setup for sequential decitabine and anti-PD-L1 treatment during chronic LCMV infection.

(B) Summary graph showing longitudinal tracking of gp33-specific CD8 T cell quantity in the peripheral blood of chronically LCMV-infected WT mice during mono- or sequentially combined decitabine and anti-PD-L1 treatments.

(C) Summary graph of gp33-specific CD8 T cell fold expansion in the PBMC after mono PD-1 blockade therapy (red bar) or sequential decitabine and PD-1 blockade (blue bar) therapy. Fold change was calculated relative to corresponding cell numbers before anti-PD-L1 treatment.

(D) Representative FACS analysis showing the frequencies of gp33-specific CD8 T cells in the spleen, lung, and liver tissues of chronically infected WT mice after indicated treatments.

(E) Representative FACS analysis showing Ki67 levels in gp33-specific CD8 T cells in the spleens of chronically infected WT mice after indicated treatments.

(F) Summary graph of the quantity of gp33-specific CD8 T cells in spleens of chronically LCMV-infected WT mice after indicated treatments.

(G) Summary graphs of the frequencies of gp33-specific CD8 T cells in the lung and liver tissues of chronically infected WT mice after indicated treatments.

(H) Summary graph of the frequencies of Ki67-expressing gp33-specific CD8 T cells in the spleens of chronically infected WT mice after indicated treatments.

N= 3–5 mice per group of two independent experiments. Error bars indicate SEM.